Hiroki Narita

Daiwa Corporate Investment Co. Ltd. (Daiwa Corporate Investment) is a private equity arm of Daiwa Securities Group Inc. and is headquartered in Tokyo, Japan. The firm was founded in 1982.

TMRC Co. Ltd. provides contract research and manufactures medicines. It develops anti-cancer products and those for cancer associated disorders. The company was founded by Hisao Ekimoto in January 2002 and is headquartered in Tokyo, Japan.

The Group's principal activity is the venture capital operation and financing. The operations are carried out through the following divisions: Investment division deals with investment in venture business of domestic and overseas companies; establishing, operation and management of assets of investment partnerships and Financing division deals with loans, leasing, and other financial services.

REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan.